Pain Syndromes

Investigational evidence from a small set of controlled trials — one RCT each for chronic low back pain and lateral epicondylitis, plus knee-osteoarthritis trials and a meta-analysis that form the strongest signal

Bleeding / Transfusion Risk

Aeromonas Infection Risk

Single-Use Only + Biohazard Disposal

Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MDTier 3 — Investigational / researchGRADE: Low

Off-label, multiple RCTsPending dedicated FDA indication

Investigational / Research Priority

Investigational / Research Priority. Use of medicinal leeches for pain syndromes is not FDA-evaluated. Evidence derives primarily from Level 3–4 studies (non-randomized comparisons and uncontrolled case series). Not recommended for routine clinical use outside formal research protocols.

Investigational Application

Pain Syndromes is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Part I — Epidemiology and Clinical Significance

50M+

US adults with chronic pain (CDC, 2023)

$560B

Annual cost — healthcare + lost productivity

39%

Chronic LBP patients with inadequate relief

1,500+

Total patients across hirudotherapy pain studies

Chronic pain is the most common reason patients seek medical care and a leading cause of disability worldwide. The opioid crisis — responsible for over 80,000 overdose deaths annually in the United States — has intensified interest in non-pharmacological pain management approaches. Leech therapy has been explored as one such approach, but the body of methodologically sound evidence is small and concentrated in a few musculoskeletal conditions.

The verifiable hirudotherapy pain literature comprises only a handful of controlled trials and one meta-analysis, totaling a few hundred patients — most of them in knee osteoarthritis. The strongest signal comes from knee-OA trials and a meta-analysis; for chronic low back pain there is a single small unblinded RCT, and for lateral epicondylitis one RCT. There is no valid clinical evidence for spinal radiculopathy, myofascial pain, or migraine. Standard care remains primary.

Part II — Multi-Pathway Pain-Relief Mechanism

The analgesic effect of hirudotherapy is not attributable to a single mechanism. Six distinct pathways have been proposed, each supported by varying degrees of preclinical and clinical evidence. The relative contribution of each pathway likely varies by pain condition, application site, and individual patient factors.

1. Gate Control (Counter-Irritation)

The leech bite creates a controlled nociceptive stimulus that may “close the gate” to chronic pain signals at the spinal cord level (Melzack & Wall, 1965). A-delta fiber activation from the bite inhibits C-fiber transmission of chronic pain. This mechanism is analogous to acupuncture and TENS but involves additional pharmacologic components from SGS.

Part IV — Systematic Review Evidence

Table 2. Systematic reviews of hirudotherapy in pain conditions
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Lauche et al. 2014	Systematic review and meta-analysis	Osteoarthritis of the knee only (3 RCTs + 1 CCT) (n=237 patients (4 trials))	Medical leech therapy vs control conditions (topical diclofenac, physiotherapy, sham/artificial-leech)	Pain, physical function, and joint stiffness (standardized mean differences)	Strong evidence for immediate pain reduction (SMD −1.05, P<0.01) and short-term pain reduction (SMD −1.00, P<0.01); immediate improvement in physical function (SMD −0.72, P<0.01) and joint stiffness (SMD −0.88, P=0.04). No serious adverse events reported. Authors call for further high-quality RCTs. Scope is limited to knee osteoarthritis — this is not a general musculoskeletal-pain meta-analysis. Three of four trials had a low risk of bias. Covered in depth on the osteoarthritis page.

Meta-Analytic Interpretation

According to the only leech-pain meta-analysis (Lauche et al., 2014, knee osteoarthritis), medical leech therapy showed standardized mean differences of about −1.0 for immediate and short-term pain — a large effect, but one derived from just four trials (3 RCTs + 1 CCT, n = 237) in knee OA alone. Effect sizes of this magnitude in largely unblinded trials are typically attenuated in subsequent sham-controlled studies, so the pooled estimate should be interpreted with caution and not generalized beyond knee OA.

Part V — Vertebrogenic Radiculopathy — Largest Evidence Base

Contrary to earlier claims on this page, there is no valid clinical evidence base for hirudotherapy in vertebrogenic radiculopathy or spinal pain. The Russian- and Kazakh-language cohorts previously listed (including a purported 280-patient series and a controlled comparison) cannot be located in PubMed and are treated here as unverifiable. No indexed study documents reduction of disc herniation size on imaging following leech therapy.

Spinal Radiculopathy — No Verifiable Evidence

No verifiable clinical study supports leech therapy for spinal radiculopathy, and there is no indexed evidence that it reduces intervertebral disc herniation size on follow-up imaging.

Mechanistic note: While local anti-inflammatory protease inhibition, microcirculation enhancement, and edema reduction are plausible mechanisms in principle, none has been demonstrated to relieve radicular pain in a controlled clinical trial. Any such use remains hypothetical and outside the evidence base.

Comparative Radiculopathy Data — Unverifiable

There is no controlled clinical evidence for hirudotherapy in radiculopathy. Any claim of complete response in a patient subgroup should be regarded as unverified.

Bottom line: Spinal radiculopathy is not an evidence-supported indication for leech therapy. Patients with radicular pain should be managed according to established guideline-based care.

Chronic Low Back Pain Protocol (Hohmann 2018)

From the German hospital standard protocol: 4–6 leeches placed paravertebrally at the level of maximum tenderness, with additional placement along the affected nerve root distribution. The combination of local anti-inflammatory delivery at the compression site and segmental neuroreflexive effects through dermatome-matched application produces multilevel pain modulation.

Part VI — Myofascial Pain Syndromes

Myofascial pain syndrome — characterized by trigger points, taut muscle bands, and referred pain patterns — has been treated with hirudotherapy only in uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. The proposed mechanism involves direct SGS delivery to trigger points combined with the counter-irritation effect of the leech bite.

Myofascial Pain — No Verifiable Evidence

There is no verifiable clinical evidence for hirudotherapy in myofascial pain syndromes.

Clinical relevance: Trigger-point directed leech application is mechanistically conceivable, but no controlled trial has shown it resolves myofascial trigger points or outperforms manual therapy. Myofascial pain is therefore not an evidence-based indication for hirudotherapy.

Part VII — Peripheral Nerve Pain

There is no verifiable clinical evidence for hirudotherapy in peripheral nerve disorders. The case series previously cited for facial nerve paralysis, sciatic neuritis, and meralgia paresthetica cannot be located in PubMed and are treated here as unverifiable. A local decongestive mechanism — reducing nerve edema and compression — is theoretically plausible but has not been demonstrated in any controlled clinical trial.

Facial Nerve Paralysis — Decongestive Mechanism

Peripheral nerve disorders such as facial nerve paralysis are sometimes cited as targets for leech therapy on a decongestive rationale — reducing local edema and nerve compression through controlled bleeding. However, no verifiable clinical study supports this use, and the decongestive mechanism remains theoretical rather than an evidence-based indication.

Part VIII — Musculoskeletal Arthrosis and Inflammatory Joint Disease

The osteoarthritis evidence is the strongest and best-established signal for leech therapy in pain — knee-OA RCTs and a meta-analysis (see the dedicated OA page ). Outside knee osteoarthritis, there is no verifiable controlled evidence for leech therapy in other arthrosis sites, TMJ arthrosis, ankylosing spondylitis, or inflammatory arthritis; the multi-joint and TMJ cohorts previously listed here cannot be confirmed in PubMed.

Table 6. Evidence for hirudotherapy in musculoskeletal arthrosis (non-OA)
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Andereya et al. 2008	RCT, sham-controlled (blinded)	Advanced osteoarthritis of the knee (n=113 (38 single / 35 double leech / 40 sham))	Single or double leech application vs a simulated "artificial leech" sham; outcomes tracked over 26 weeks	KOOS, WOMAC, VAS pain, and pain-medication use	KOOS, WOMAC, and VAS improved in all three groups; improvements were statistically significant and sustained in the leech groups, with the greatest and most durable benefit in the double-application group. Whether the benefit reflects leech-derived active substances, placebo, or expectation could not be determined. One of the few blinded, sham-controlled leech RCTs — knee OA, not radiculopathy. Its own authors caution that placebo and expectation effects cannot be excluded. Relevant here only as the strongest-design signal in the leech-pain literature (knee OA).

Multi-Joint Arthrosis — No Verifiable Evidence

There is no verifiable clinical evidence for leech therapy in multi-joint arthrosis outside the knee.

What is established: The evidence that does hold up is for knee osteoarthritis specifically (see the osteoarthritis page). Extrapolation to other joints is not supported by controlled data.

Ankylosing Spondylitis — No Verifiable Evidence

There is no verifiable clinical evidence for hirudotherapy in ankylosing spondylitis. Ankylosing spondylitis should be managed according to current rheumatology guidelines, including NSAIDs and, where indicated, biologic therapy; leech therapy has no established role.

Part IX — Comparison with Established Non-Pharmacological Approaches

Approach	Evidence Quality	Effect Size	Blinding Feasible?	Total Patients Studied	Guideline Status
Physical therapy	High (many RCTs)	Moderate (d = 0.3–0.6)	Difficult	50,000+	Strongly recommended
Acupuncture	Moderate (many RCTs)	Small–moderate (d = 0.3–0.5)	Partially (sham needling)	20,000+	Conditionally recommended (ACP)
TENS	Moderate	Small (d = 0.2–0.4)	Yes (sham TENS)	10,000+	Conditionally recommended
Cognitive behavioral therapy	High (many RCTs)	Moderate (d = 0.4–0.6)	Difficult	10,000+	Strongly recommended
Hirudotherapy	Low (3 RCTs, Level 3–4 cohorts)	Large (d = 0.8–1.1) — likely inflated	Very difficult	1,500+	Not in guidelines

Effect Size Paradox

The paradoxically large effect sizes reported for hirudotherapy (d = 0.8–1.1) compared to established non-pharmacological approaches should raise caution rather than enthusiasm. Large effect sizes in unblinded studies often reflect bias and placebo effects rather than true treatment superiority. The inability to adequately blind leech therapy is a fundamental limitation. In pain conditions where placebo response rates average 30–40%, this makes it impossible to determine how much of the observed benefit is pharmacological vs psychological.

Part X — Treatment Protocols by Condition

The following protocols synthesize application parameters from published studies and the Essen-Mitte Hospital standard protocol (Michalsen, Roth & Dobos, 2007). All protocols assume standard pre-procedure screening and antibiotic prophylaxis per institutional guidelines.

Condition	Leeches / Session	Application Site	Sessions	Frequency	Source
Chronic low back pain	4–6	Bilateral lumbar paraspinal muscles at maximum tenderness	1 (single session)	—	Hohmann 2018
Vertebrogenic radiculopathy	4–9	Nerve root exits → interspinous ligaments → paravertebral trigger points → facet joints → nerve root course	6–12	Every 3–4 days	Clinical practice (unverified)
Lateral epicondylitis	2–4	Lateral epicondyle region	1 (single session)	—	Bäcker 2011
Myofascial pain / trigger points	3–8	Directly over trigger points / acupuncture points	3–8	1–2× per week	Clinical practice (unverified)
Shoulder periarthritis	6–10	Periarticular zone of shoulder	8–10	1–2× per week	Clinical practice (unverified)
Sciatic neuritis / neuralgia	5–16	Along nerve root course and sciatic nerve	2–8	Variable	Clinical practice (unverified)
Facial nerve paralysis	4–6	Mastoid process (affected side)	4–10	Every other day	Clinical practice (unverified)
Multi-joint arthrosis	2–3	Algic (pain) points of affected joint	5–10	Every other day	Clinical practice (unverified)
Migraine	4–6	Temporal and retroauricular area	2	—	Clinical practice (unverified)

Part XI — Safety Profile and Drug Interactions

Pain conditions frequently involve concurrent pharmacotherapy that may interact with hirudotherapy. The following drug interaction considerations are specifically relevant to pain patients.

Drug Class	Interaction	Risk Level	Clinical Implication
NSAIDs (ibuprofen, naproxen, diclofenac)	Additive antiplatelet + anti-inflammatory effects	Moderate	Prolonged post-detachment bleeding. Hold NSAIDs 48h before if feasible.
Anticoagulants (warfarin, DOACs)	Additive anticoagulant effect	High	Excessive bleeding risk. Generally contraindicated without coagulation monitoring.
Antiplatelet agents (aspirin, clopidogrel)	Additive platelet inhibition (apyrase + antiplatelet drug)	High	The 17% reduction in ADP-induced aggregation from SGS compounds the antiplatelet effect.
Opioid analgesics	No direct pharmacologic interaction	Low	Pain reduction from hirudotherapy may allow dose reduction — a potential benefit in opioid-dependent patients.
Corticosteroids (oral, injected)	Immunosuppressive effect increases bite-site infection risk	Moderate	Consider antibiotic prophylaxis for patients on chronic corticosteroids. Eglin c may potentiate glucocorticoid activity.
Muscle relaxants	No known interaction	Low	May be used concurrently with hirudotherapy for spinal pain.

Key Limitation: Blinding

The inability to adequately blind leech therapy is the single most important limitation of the pain evidence. Patients know whether a leech is applied. Proposed sham controls — mechanical leech devices, defanged leeches, or deactivated leech bites — have not been validated. Until adequate blinding is achieved, the true magnitude of the pharmacologic analgesic effect cannot be determined.

Part XII — Critical Evidence Appraisal

The pain syndromes evidence must be assessed in the context of the fundamental methodologic challenges unique to hirudotherapy research:

Limitation	Impact	Mitigation Strategy
Inadequate blinding	Inflated effect sizes (estimated 40–60% attenuation in sham-controlled replication)	Develop validated mechanical leech sham device
Small sample sizes	RCTs: n = 40–50. Underpowered for clinically meaningful effect detection	Multicenter trials with n ≥ 100 per arm
Short follow-up	Maximum 3 months in RCTs. Chronic pain requires 6–12 month outcomes	Extended follow-up protocols
Multimodal confounding	Most cohort studies used HT as part of comprehensive treatment. Isolated effect unknown.	Factorial designs separating HT from adjuncts
Publication bias	Positive results more likely published	Prospective trial registration
No dose-response data	Optimal leech number, session frequency, and treatment duration are not established	Dose-finding studies (2 vs 4 vs 8 leeches)

Clinical Recommendation

Peripheral nerve disorders such as facial nerve paralysis are sometimes cited as targets for leech therapy on a decongestive rationale — reducing local edema and nerve compression through controlled bleeding. However, this decongestive mechanism remains theoretical and has not been demonstrated in any controlled clinical trial; it is not an evidence-based indication.

Key Takeaways

1. The strongest signal for leech therapy in pain is knee osteoarthritis — a meta-analysis of 4 trials (n = 237; Lauche 2014) and blinded RCTs such as Andereya 2008 — covered in depth on the osteoarthritis page.

2. Two real RCTs exist outside knee OA: chronic low back pain (Hohmann 2018, VAS group difference −25.2) and lateral epicondylitis (Bäcker 2011, pain-sum difference −49.0 at day 7). Both are small and unblinded and likely overestimate the true effect.

3. The meta-analytic effect size (d = 1.09) is unusually large for a pain intervention and should be interpreted with caution pending sham-controlled replication studies.

4. Six mechanistic pathways — gate control, anti-inflammatory, microcirculation, endogenous opioids, local decongestive, and neurotrophic — may contribute to pain relief, but their relative contributions are unknown.

5. There is no verifiable evidence for leech therapy in myofascial pain, spinal radiculopathy, peripheral nerve pain, or migraine — the previously listed Russian/Kazakh cohorts could not be located in PubMed.

6. Outside knee osteoarthritis there is no verifiable controlled evidence for leech therapy in other arthrosis sites or ankylosing spondylitis; those case series could not be confirmed in PubMed.

7. The inability to adequately blind leech therapy is the fundamental limitation. In pain conditions where placebo response rates average 30–40%, this makes it impossible to isolate the pharmacologic component.

8. All pain applications are Tier 3 (Investigational) with no FDA evaluation. Evidence does not support routine clinical use outside formal research protocols.

Research Agenda

Sham-controlled RCT for chronic LBP (n ≥ 200): Using validated mechanical leech sham devices. Primary endpoint: VAS at 6 months. This single study would resolve the central question of whether the analgesic effect is pharmacologic or nonspecific.
Multicenter radiculopathy RCT (n ≥ 100): Randomized comparison of hirudotherapy + manual therapy vs manual therapy + sham, with MRI assessment of disc changes and 12-month remission duration endpoint.
Dose-finding study: Comparison of 2 vs 4 vs 8 leeches for LBP/epicondylitis. No dose-response data exist for any pain condition.
Mechanistic biomarker study: Simultaneous measurement of inflammatory markers (CRP, IL-6, TNF-α), β-endorphin, regional blood flow (Doppler), and neurotrophic markers (BDNF, phospho-TrkB) before and after leech application.
Myofascial trigger point resolution study : Ultrasound-guided quantification of trigger point size and stiffness before and after hirudotherapy, with sham control.
Head-to-head comparison with acupuncture : Both involve needle-like skin penetration with proposed counter-irritation mechanisms. A direct comparison would clarify whether the SGS pharmacologic component provides additional benefit.
Opioid reduction feasibility study: In patients on chronic opioid therapy for LBP, assess whether adjunctive hirudotherapy enables opioid dose reduction — a clinically relevant endpoint in the context of the opioid crisis.

Related Research

Clinical Trials2023

Acrometastasis as a mimic of complex regional pain syndrome

Complex regional pain syndrome (CRPS) is characterized by chronic pain disproportional to any inciting event, and is associated with poor quality of life, and large clinical, healthcare, and societal costs.

Leech HX et al. · Interventional pain medicine

Clinical Trials2019

Beneficial effects of hirudotherapy in a chronic case of complex regional pain syndrome

We report about hirudotherapy in a patient with chronic complex regional pain syndrome (CRPS) in the right hand. CRPS is a multifactorial disease associated with disabling pain as well as sensory and motor deficits.

Kulbida R, Mathes A, Loeser J · Journal of integrative medicine

Clinical Trials2014

Leech Therapy for Lateral Epicondylitis — RCT

Randomized controlled trial evaluating leech therapy versus topical diclofenac for chronic lateral epicondylitis (tennis elbow). Demonstrated significant pain reduction and improved grip strength in the leech therapy group, extending the clinical evidence for hirudotherapy beyond osteoarthritis to tendinopathies.

Michalsen A et al. · Clinical Journal of Pain

Clinical Trials2013

Medicinal leech therapy in pain syndromes: a narrative review

Narrative review on leech therapy's analgesic effect across multiple pain syndromes (osteoarthritis, epicondylitis, hematoma, thrombophlebitis, varicose veins); the saliva contains anti-inflammatory, thrombolytic, anti-coagulant and circulation-enhancing molecules, though a specific analgesic compound has not been identified.

Koeppen D et al. · Wiener Medizinische Wochenschrift

Clinical Trials2025

Reviving ancient wisdom: exploring the effectiveness of Jalaukavacharan in pain management and wound healing — a case series

Ayurvedic case series of multiple chronic pain and wound conditions managed via jalaukavacharan (leech-application bloodletting). Reports VAS pain-score reductions and improved wound healing across diabetic foot, varicose ulcer, and arthritis cases.

Gautam A et al. · Alternative therapies in health and medicine

Clinical Trials2024

Pulsed Radiofrequency in the Management of Postsurgical Abdominal Wall Chronic Pain: A Report From a Single Oncological Center

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Trovisco et al. · Cureus